Background: Bacterial vaginosis (BV) affects 10-30% of women and recurs in 15-30% within 3
Background
Bacterial vaginosis (BV), a polymicrobial pathogenic shift in the vaginal flora, is the most prevalent cause of vaginitis worldwide, affecting 10-30% of women in the general population, and 40-50% of women who are sex workers, HIV-positive, or attending sexually transmitted infection (STI) clinics [1] [2] . BV increases the risk of preterm birth by up to 45% [3] , and is associated with a doubling in risk of pelvic inflammatory disease [4] [5] . The risk of HIV seroconversion is up to 2.5 times greater for women with BV [6] [7] , and BV increases the risk of HIV transmission through increased genital viral expression [8] [9] . Further, BV puts women at increased risk of acquiring other STIs, such as gonorrhea and chlamydia [10] [11] . Recurrence after treatment with a recommended antibiotic regimen is common: 15-30% within 3 months [12] [13] [14] [15] [16] [17] , and 60-80% by 12 months [18] .
BV is not considered an STI [19] . However, sexual exposure increases BV risk. A metaanalysis of 28 studies located worldwide estimated a 20% protective effect of condom use on BV, and a 60% increased risk of BV for women with new or multiple male sex partners [1] . The overlapping risks for BV and STIs provide epidemiologic support for sexual transmissibility of BV-associated bacteria [20] . Case control studies have demonstrated concordance of urethral and vaginal recovery of Gardnerella vaginalis among couples where the woman has BV [21] [22] .
Broad survey of the penile bacterial microbiota through pyrosequencing of the 16s rRNA gene has identified a substantial prevalence and abundance of common BV-associated bacteria in uncircumcised men [23] [24] . Results from the randomized controlled trial (RCT) of male circumcision in Rakai, Uganda, found a 60% reduction in severe BV and 40% reduction in any BV in female partners of circumcised vs. uncircumcised men at one year follow-up [25] . These data suggest the penile environment may serve as a reservoir for BV-associated bacteria. If antibiotic treatment in men can reduce carriage of BV-associated bacteria, this may lead to reduced BV recurrence and long term reduction in prevalence and associated morbidity.
Five of 6 RCTs did not report a statistically significant beneficial effect of male partner treatment with antibiotics on reducing BV recurrence [12] [13] [14] [15] [16] [17] . These trials form the basis for current Centers for Disease Control and Prevention and World Health Organization recommendations: treatment of the male partner is not recommended as part of BV treatment [19, 26] . In light of epidemiologic evidence across different populations and over time, and recent findings from results of genital microbiota analyses, these 6 RCTs of male sexual partner treatment for improved BV outcomes were reviewed to assess the validity of their results.
Methods

Search Methodology
PubMed was searched using the keywords "sexual partner(s)" or "sexual contact(s)" and "vaginitis" or "vaginosis" or "vaginalis" (no field restriction), limited to "randomized controlled trial". Among 33 (32 English language) articles returned by the search, six trials of treatment of sexual partners [12] [13] [14] [15] [16] [17] 
Review Methodology and Data Extraction
Five of the trials were published 1985-1993 [12] [13] [14] [15] [16] [17] [17] did not follow the CONSORT statement. A participant flow diagram was generated for each trial (Figures 1-6 ). Trials are summarized according to CONSORT guidelines for items to be included when reporting a randomized trial in a journal abstract [27] . Each article was reviewed to complete the 25-item CONSORT checklist to assess potential risk of bias in individual studies. Potential sources of bias in design and reporting are summarized in the text and detailed for each trial in Table 2 , adapted from the CONSORT checklist. Study investigators were not contacted to verify data or obtain additional information. Flow diagrams and checklists were completed by a single reviewer (SDM).
Statistical Analyses
One trial partially reported results in terms of absolute or relative effect sizes with precision estimates. For this review, when denominator and numerator data were available, absolute differences and risk ratios (RRs) with binomially obtained 95% confidence intervals (CIs) were estimated using immediate commands in Stata/SE v11.2.
Sample Size
Five trials did not report sample size calculations. For all six trials, post-hoc power analyses were conducted (Two Independent Proportions Power Analysis, Power and Sample Size [PASS] v11 [28] ) to determine the probability of rejecting the null hypothesis: (1) for observed relative effect sizes >10%, and (2) if the observed effect size were <10%, for the smallest relative effect size detectable with >80% power based. Table 1 summarizes trial setting, interventions, and primary results of each trial. CONSORT flow diagrams are incomplete with regards to randomization (Swedberg et al. [12] , Figure 1 ) and follow-up (Vejtorp et al. [13] , Figure 2 ) due to insufficient reporting. None of the trials reported recruitment methods or participation rates. Three of the trials explicitly stated that women had to be symptomatic to be eligible. None of the trials reported eligibility criteria for male partners or nature or duration of the relationship. Male circumcision status was reported only in the trial by Moi et al. [15] , stating that "few" men were circumcised. Gardnerella vaginalis cultures were obtained from women in three trials [13, [15] [16] and from a select subset of men in the trial by Moi et al. [15] . In all trials where clinical diagnosis of BV is an outcome, Amsel's criteria [29] are used, except in the trial by Swedberg et al. [12] .
Results
Potential sources of bias in each trial are detailed in Table 2 . None of the trials reported the mechanism of allocation concealment, how randomization was implemented, or methods for maintaining blinding of researchers. Female participants' baseline demographics [12] [13] 15] and clinical characteristics [12, 17] are not reported. Male participants' baseline demographic and clinical characteristics are not reported in three trials [12] [13] 15] . Only the trial by Vutyanavich et al. [16] reported adherence in women, and adherence in men was reported only in the trials by Vutyanavich et al. [16] and Colli et al. [17] . With the observed sample size, there was 14% power to reject the null hypothesis for the observed difference in relapse between intervention and control women (21% vs. 16%); >80% power is achieved for effect size >67.5% assuming 20% rate of outcome in controls. In this multicenter, parallel arm, randomized trial, women were treated with clindamycin 2% vaginal cream at bedtime for 7 days and partners were randomized 1:1 to receive clindamycin 150mg by mouth 4 times daily for 7 days (intervention, n=69) or placebo (control, n=40).
Results of Trials
Women were recruited from 14 outpatient clinics in Italy. Recurrence was defined as the presence of clue cells plus at least 2 other Amsel's criteria [29] . Recurrence for intervention arm The authors conclude that their findings do not support male treatment for reducing short term BV recurrence. With the observed sample size, >80% power is achieved only for effect sizes >63%, assuming a 30% BV recurrence rate among controls.
Discussion
While the RCT is the gold standard for assessing efficacy, biased results from poorly designed and reported trials can mislead decision making [30] . The primary limitations of these 6 trials were insufficient randomization methods, limited power, use of sub-optimal treatment regimens, and unknown adherence levels.
In all 6 trials, the limited details regarding randomization, and overt deficiencies in some studies, prohibit knowledge of whether randomization was successful. Thus the advantages of randomization (elimination of selection bias, facilitation of blinding, adoption of probability theory to explain chance differences between groups [30] ) are not ensured.
Three trials found an association in a protective direction between male partner treatment and BV recurrence. While Mengel et al. [14] reported some statistically significant (p<0.05) improvements in BV cure and symptom resolution in women with treated partners, no tabular data or effect sizes are reported, making it ineligible for quantitative consideration. In the trial by Vejtorp et al. [13] , at 5 weeks there was a 15% reduction in BV diagnosed and a 36% reduction in culture detected G. vaginalis for women whose partners were treated compared to those whose were not. The trial by Vutyanavich et al. [16] found a 13% increase in clinical cure of BV at 4 weeks for women whose partners were treated compared to those whose partner received placebo. The trial by Moi et al. [15] found an association in a harmful direction: the risk of relapse of BV at 12 weeks was 33% greater for women whose partners were treated compared to those whose were not. Two trials observed associations close to the null between partner treatment and outcome: an RR of 1.06 for cure in the trial by Swedberg et al. [12] , and an RR of 1.06 for recurrence in the trial by Colli et al. [17] . For commonly occurring and recurrent outcomes such as BV, even modest treatment effects can be of public health significance [30] .
None of these 6 trials were powered to detect modest (10-20%) effects -harmful or beneficialof male treatment on BV outcomes in women; the smallest detectable effect size was 26% in the trial by Vutyanavich et al. [16] . The rate of relapse varied widely among trials -from 16% to 37% -due to different outcome definitions and time at assessment. To be adequately powered to detect modest differences, future studies will need to consider a broad range of recurrence rates.
Meta-analysis was not conducted as a potential solution due to significant bias in these studies; pooled analysis can be inappropriate if the methodologic quality of individual trials is inadequate [31] .
Five trials employed sub-optimal treatment in women, which would lead to lower cure rates and higher rates of recurrence, attenuating potential effects of male partner treatment. The trial by Swedberg et al. [12] included single dose metronidazole for treating women, a treatment regimen that is no longer recommended. Three trials [13] [14] [15] employed a 2-gram dose of metronidazole administered on day 1 and day 3; to the author's knowledge, no randomized trials assessing the efficacy of this treatment regimen have been conducted. The trial by Vutynavich et al. [16] treated women with a single 2-gram dose of tinidazole [19] . Oral tinidazole 2g given once daily for 2 days is an alternative CDC-recommended treatment for BV with similar efficacy to the 7-day course of metronidazole [32] . Compared to metronidazole, tinidazole has similar maximum concentration and penetration in various tissues [33] [34] , but with superior penetration in male genital tissue [35] and lower side effects profile [34] . These traits, plus higher likelihood of adherence and comparable costs [36] , make tinidazole a well-suited regimen to test the effects of male treatment on penile bacterial carriage and BV outcomes in women.
Adherence to BV treatment in women was not reported in any of the trials, but may be inferred as complete in the trial by Vutyanavich et al. [16] , due to use of directly observed single dose therapy. Adherence to treatment in men was reported in the trials by Vutyanavich et al. [16] and Colli et al. [17] . In the trial by Vutyanavich et al. [16] , 4 men in the tinidazole group and 2 men in the placebo group were reported by their female partners as refusing medication. In the study by Colli et al. [17] , non-adherence was 19% (27 men of 139 randomized), and did not differ by treatment arm. While not reported in the other trials and not addressed in analyses, nonadherence in women or male partners may have led to attenuation of a potential effect of treatment in men on BV recurrence in female partners. Further, it is unknown whether any of the treatment regimens significantly reduced BV-associated bacteria from the penile microbiota, as microbiologic studies of the penile microbiota before and after treatment were not conducted. This review is limited by incomplete reporting of methods and data in individual trials.
Incomplete reporting should be considered separately from methodologic flaws; a trial that is well-designed and well-conducted may be poorly reported. However, several evaluations of RCTs find that inadequate and unclear reporting are associated with inaccurate estimation of efficacy, independent of study design [37] [38] , that the design and quality of trials are correlated with the quality of reporting [39] , and that contact with original authors leads to minimal improvements in reporting [40] .
Conclusions
The trials that assessed the effect of male treatment on BV recurrence in women did not find a beneficial effect, but were significantly flawed. Epidemiologic and microbiologic evidence indicating that BV-associated bacteria may be transferrable between male and female sex partners continues to mount. Disregarding this disconnect based on the results of the trials may be a failed opportunity to expand our understanding of BV transmission dynamics. In a recent review of current knowledge of BV, Marrazzo summarizes potential risks for BV: sexual partners, specific sexual practices, and the vaginal microbiota [41] . While it would be convenient to identify a sole mechanism of pathogenesis and a single causative bacterium, BV is multifactorial, with direct effects from the individual-and couple-level genital microbiota as well as mediation by individual-and couple-level behavior. To carefully examine whether BVassociated bacteria are transferred between sex partners, the next steps are to apply methods such as pyrosequencing to study the temporal correlation between the penile and vaginal microbiota; assess factors affecting the couples-level genital microbial environments; and determine whether efficacious BV treatment, such as tinidazole, reduces BV-associated bacteria in the penile microbiota. By current standards, it is unlikely that any of the 6 trials would be considered conclusive. To generate an accurate evidence base for treatment recommendations, wellconducted RCTs are needed to determine whether antibiotic treatment in men can reduce BV and associated sequelae in female sex partners.
